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Dear Editor,  
The ongoing pandemic of COVID-19 has forced us to consider 
using available drugs in the shortfall of vaccines and established 
treatment. Cotrimoxazole is one of the oldest drugs presently 
used in the prevention and treatment of opportunistic infections 
in the human immune deficiency virus (HIV) etc. It is a 
combination of two drugs Trimethoprim and Sulfamethoxazole.  
     Cotrimoxazole is a potent broad-spectrum antibiotic with 
antifungal, antiprotozoal, activity. The rationale behind the use 
of Cotrimoxazole is its anti-inflammatory and 
immunomodulatory action. The mortality among the COVID-
19 patients is mainly due to the acute respiratory distress 
syndrome or pulmonary embolism and respiratory failure 
mediated by cytokine storm due to unopposed multiplication of 
cascade of inflammatory mediators [1]. The immunomodulatory 
and anti-inflammatory activity of the Cotrimoxazole is seen in 
many studies [2.3]. The ARROW trial showed lower 
concentrations of plasma pro-inflammatory markers like C 
reactive protein (CRP), Interleukin 6 in continuous 
Cotrimoxazole prophylaxis, suggesting its role as anti-
inflammatory and immunomodulation [3]. The role of 
Interleukin 6 (IL6) and Tumour necrosis factor-alpha (TNF α) 
in the pathogenesis of COVID-19 mortality is well documented 
[4]. The role of Cotrimoxazole in the suppression of TNF α is 
also well documented [5]. Lymphopenia is associated with 
adverse outcomes in COVID-19. Cotrimoxazole has shown an 
increase in lymphocyte count in a short and long therapy 
duration, but these study findings are not consistent with few 
other studies; however, no significant impact of Cotrimoxazole 
was seen on immune activation of CD8 T cells [6-8]. Hence it 
should be reserved only for critically ill patients. Oxidative 
stress has an important aspect of the cytokine storm, which is 
also reduced by Cotrimoxazole [9]. Various side effects are 
mentioned in the literature. This cost-effective old drug is well 
tolerated among the population with the concomitant use of 
folic acid; moreover, it also looks after the secondary infections 







COVID-19: Coronavirus Disease-19; HIV: Human Immune Deficiency 
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